An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis

Messenger RNA (mRNA) therapies have recently gained tremendous traction with the approval of mRNA vaccines for the prevention of SARS-CoV-2 infection. However, manufacturing challenges have complicated large scale mRNA production, which is necessary for the clinical viability of these therapies. Not only can the incorporation of the required 5’ 7-methylguanosine cap analog be inefficient and costly, in vitro transcription (IVT) using wild-type T7 RNA polymerase generates undesirable double-stranded RNA (dsRNA) byproducts that elicit adverse host immune responses and are difficult to remove at large scale. To overcome these challenges, we have engineered a novel RNA polymerase, T7-68, that co-transcriptionally incorporates both di- and tri-nucleotide cap analogs with high efficiency, even at reduced cap analog concentrations. We also demonstrate that IVT products generated with T7-68 have reduced dsRNA content.

[1]  A. Hui,et al.  The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines , 2022, Cancer Treatment Reviews.

[2]  L. Abu-Raddad,et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.

[3]  How biomanufacturing can save the world , 2021, Nature Biotechnology.

[4]  Byung-Kwan Cho,et al.  Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency , 2021, Molecular & Cellular Toxicology.

[5]  Irena Vlatkovic.  Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety , 2021, Biomedicines.

[6]  J. Meier,et al.  Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines , 2021, ACS central science.

[7]  Serena Tinari.  The EMA covid-19 data leak, and what it tells us about mRNA instability , 2021, BMJ.

[8]  M. Houston,et al.  Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap® Analog by In Vitro Transcription , 2021, Current protocols.

[9]  S. Pascolo.  Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype , 2021, Viruses.

[10]  E. Nowak,et al.  Structural Insights into the Interaction of Clinically Relevant Phosphorothioate mRNA Cap Analogs with Translation Initiation Factor 4E Reveal Stabilization via Electrostatic Thio-Effect , 2021, ACS chemical biology.

[11]  Shrutika Mintri,et al.  Impact of mRNA chemistry and manufacturing process on innate immune activation , 2020, Science Advances.

[12]  D. Weissman,et al.  Recent advances in mRNA vaccine technology. , 2020, Current opinion in immunology.

[13]  J. Rehwinkel,et al.  RIG-I-like receptors: their regulation and roles in RNA sensing , 2020, Nature Reviews Immunology.

[14]  S. Gurunathan,et al.  The promise of mRNA vaccines: a biotech and industrial perspective , 2020, npj Vaccines.

[15]  A. Iwasaki,et al.  RIG-I Recognition of RNA Targets: The Influence of Terminal Base Pair Sequence and Overhangs on Affinity and Signaling. , 2019, Cell reports.

[16]  G. Tzertzinis,et al.  Synthesis of low immunogenicity RNA with high-temperature in vitro transcription , 2019, bioRxiv.

[17]  U. Şahin,et al.  A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA , 2019, Molecular therapy. Nucleic acids.

[18]  S. Hur.  Double-Stranded RNA Sensors and Modulators in Innate Immunity. , 2019, Annual review of immunology.

[19]  Craig T Martin,et al.  3' end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in characterâ•fiâ•fiRNA-Seq analyses , 2019 .

[20]  A. Niedzwiecka,et al.  Modified ARCA analogs providing enhanced translational properties of capped mRNAs , 2018, Cell cycle.

[21]  Anton P. McCaffrey,et al.  Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification , 2018, Molecular therapy. Nucleic acids.

[22]  Sadeem Ahmad,et al.  An origin of the immunogenicity of in vitro transcribed RNA , 2018, bioRxiv.

[23]  Aaron J. Martin,et al.  Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  R. Sprangers,et al.  A general method for rapid and cost-efficient large-scale production of 5′ capped RNA , 2016, RNA.

[25]  G. B. Robb,et al.  mRNA capping: biological functions and applications , 2016, Nucleic acids research.

[26]  R. Condit,et al.  Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutant. , 2016, Virology.

[27]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[28]  G. Sen,et al.  dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  D. Weissman,et al.  HPLC purification of in vitro transcribed long RNA. , 2013, Methods in molecular biology.

[30]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[31]  D. Weissman,et al.  Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L , 2011, Nucleic acids research.

[32]  D. Venzon,et al.  TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection , 2011, The Journal of Immunology.

[33]  Philip C. Bevilacqua,et al.  Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation , 2010, Nucleic acids research.

[34]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  D. Davies,et al.  Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA , 2008, Science.

[36]  R. Rhoads,et al.  Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. , 2004, RNA.

[37]  A. Dallas,et al.  Principles of Nucleic Acid Cleavage by Metal Ions , 2004 .

[38]  R. Rhoads,et al.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. , 2001, RNA.

[39]  L. Brieba,et al.  Misincorporation by wild-type and mutant T7 RNA polymerases: identification of interactions that reduce misincorporation rates by stabilizing the catalytically incompetent open conformation. , 2000, Biochemistry.

[40]  J. Kern,et al.  Application of a Fed‐Batch System To Produce RNA by In Vitro Transcription , 1999, Biotechnology progress.

[41]  K. Nierhaus,et al.  Self-coded 3′-Extension of Run-off Transcripts Produces Aberrant Products during in Vitro Transcription with T7 RNA Polymerase (*) , 1995, The Journal of Biological Chemistry.

[42]  O. Uhlenbeck,et al.  RNA template-directed RNA synthesis by T7 RNA polymerase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Schumacher,et al.  Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts. , 1991, Nucleic acids research.